Saxagliptin (BMS-477118,Onglyza) (BioDeep_00001103446)
代谢物信息卡片
Saxagliptin (BMS-477118,Onglyza)
化学式: C18H25N3O2 (315.194667)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
InChI: InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14-,15-,17?,18?/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yangchen Tang, Mengli Yan, Zemin Fang, Song Jin, Tingjuan Xu. Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice.
BMJ open diabetes research & care.
2024 May; 12(3):. doi:
10.1136/bmjdrc-2023-003837. [PMID: 38719505] - Chao Yu, Mingyu Cui, Yifeng Yin, Fengmei Zhu, Yue Sui, Xueying Yan, Yingli Gai. Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats.
Biopharmaceutics & drug disposition.
2023 Dec; 44(6):396-405. doi:
10.1002/bdd.2374. [PMID: 37596705] - Sabry M Attia, Sheikh F Ahmad, Ahmed Nadeem, Mohamed S M Attia, Mushtaq A Ansari, Abdelkader E Ashour, Norah A Albekairi, Mohammed A Al-Hamamah, Ali A Alshamrani, Saleh A Bakheet. Saxagliptin, a selective dipeptidyl peptidase-4 inhibitor, alleviates somatic cell aneugenicity and clastogenicity in diabetic mice.
Mutation research. Genetic toxicology and environmental mutagenesis.
2023 Nov; 892(?):503707. doi:
10.1016/j.mrgentox.2023.503707. [PMID: 37973297] - Yahya Alhamhoom, Gundawar Ravi, Riyaz Ali M Osmani, Umme Hani, Gowrav M Prakash. Formulation, Characterization, and Evaluation of Eudragit-Coated Saxagliptin Nanoparticles Using 3 Factorial Design Modules.
Molecules (Basel, Switzerland).
2022 Nov; 27(21):. doi:
10.3390/molecules27217510. [PMID: 36364338] - Morgan A Butrovich, Weifeng Tang, David W Boulton, Thomas D Nolin, Pradeep Sharma. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.
Journal of clinical pharmacology.
2022 Aug; 62(8):1018-1029. doi:
10.1002/jcph.2043. [PMID: 35247279] - Suat Tekin, Asiye Beytur, Murat Cakir, Aslı Taslıdere, Yavuz Erden, Cigdem Tekin, Suleyman Sandal. Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats.
Archives of physiology and biochemistry.
2022 Jun; 128(3):608-618. doi:
10.1080/13813455.2020.1715442. [PMID: 31979992] - Wenjing Ni, Yan Pan, Huijuan Yang, Wei Li, Yan Sun, Yu Xu, Weidong Chen. [Saxagliptin alleviates kidney injury in diabetic rats by down-regulating the expression of mammalian target of rapamycin (mTOR)].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2022 May; 38(5):406-411. doi:
NULL. [PMID: 35603648] - Marwa Mohsen, Ahmed A Elberry, Alaa Mohamed Rabea, Doaa Mahmoud Khalil, Mohamed E A Abdelrahim, Raghda R S Hussein. A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.
Canadian journal of diabetes.
2022 Mar; 46(2):134-141.e2. doi:
10.1016/j.jcjd.2021.07.004. [PMID: 35181219] - Hany H Arab, Ahmed M Ashour, Amany M Gad, Ayman M Mahmoud, Ahmed M Kabel. Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage.
Life sciences.
2021 Sep; 280(?):119743. doi:
10.1016/j.lfs.2021.119743. [PMID: 34166711] - Yuzhan Zhang, Ke Li, Yan Li, Weihao Zhao, Li Wang, Zhao Chen, Xiaotao Ma, Tian Yao, Jinhua Wang, Wei Dong, Xiancheng Li, Xuefei Tian, Rongguo Fu. Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells.
Pharmacological research.
2021 07; 169(?):105630. doi:
10.1016/j.phrs.2021.105630. [PMID: 33932609] - Herbert Nar, Gisela Schnapp, Oliver Hucke, Timothy C Hardman, Thomas Klein. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
ChemMedChem.
2021 05; 16(9):1425-1426. doi:
10.1002/cmdc.202000921. [PMID: 33348462] - Amel Rezki, Marinos Fysekidis, Sabrina Chiheb, Eric Vicaut, Emmanuel Cosson, Paul Valensi. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance.
Nutrition, metabolism, and cardiovascular diseases : NMCD.
2021 04; 31(4):1257-1266. doi:
10.1016/j.numecd.2020.12.025. [PMID: 33618922] - Marwa Mohsen, Ahmed A Elberry, Alaa Mohamed Rabea, Mohamed E A Abdelrahim, Raghda R S Hussein. Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
International journal of clinical practice.
2021 Mar; 75(3):e13769. doi:
10.1111/ijcp.13769. [PMID: 33068301] - Paul J Besseling, Tobias T Pieters, Isabel T N Nguyen, Petra M de Bree, Nel Willekes, Adele H Dijk, Dominique M Bovée, Ewout J Hoorn, Maarten B Rookmaaker, Karin G Gerritsen, Marianne C Verhaar, Hendrik Gremmels, Jaap A Joles. A plasma creatinine- and urea-based equation to estimate glomerular filtration rate in rats.
American journal of physiology. Renal physiology.
2021 03; 320(3):F518-F524. doi:
10.1152/ajprenal.00656.2020. [PMID: 33522412] - Raafat A Abdel-Aal, Mahran S Abdel-Rahman, Soad Al Bayoumi, Laila A Ali. Effect of stevia aqueous extract on the antidiabetic activity of saxagliptin in diabetic rats.
Journal of ethnopharmacology.
2021 Jan; 265(?):113188. doi:
10.1016/j.jep.2020.113188. [PMID: 32783985] - Akhtar Rasul, Safirah Maheen, Hafeez Ullah Khan, Maria Rasool, Shahid Shah, Ghulam Abbas, Khurram Afzal, Fatima Tariq, Irum Shahzadi, Muhammad Hassham Hassan Bin Asad. Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior.
BioMed research international.
2021; 2021(?):3849093. doi:
10.1155/2021/3849093. [PMID: 34722762] - Yuejuan Qin, John Adams, Carolina Solis-Herrera, Curtis Triplitt, Ralph DeFronzo, Eugenio Cersosimo. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Diabetes care.
2020 10; 43(10):2519-2527. doi:
10.2337/dc19-1993. [PMID: 32694214] - Xiu Feng, Qingwei Gu, Gu Gao, Lu Yuan, Qian Li, Ying Zhang. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Annales d'endocrinologie.
2020 Oct; 81(5):476-481. doi:
10.1016/j.ando.2020.07.1113. [PMID: 32822653] - Ayano Kubo, Teruo Hidaka, Maiko Nakayama, Yu Sasaki, Miyuki Takagi, Hitoshi Suzuki, Yusuke Suzuki. Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
BMC nephrology.
2020 09; 21(1):402. doi:
10.1186/s12882-020-02060-9. [PMID: 32948146] - Safirah Maheen, Akhtar Rasul, Muhammad Hanif, Hafeez Ullah Khan. Lipospheres for Simultaneous Controlled Release and Improved Pharmacokinetic Profiles of Saxagliptin-Enalapril: Formulation, Optimization, and Comparative In Vitro-In Vivo Evaluation.
AAPS PharmSciTech.
2020 Jul; 21(5):188. doi:
10.1208/s12249-020-01733-w. [PMID: 32651896] - Lars Johansson, Paul D Hockings, Eva Johnsson, Nalina Dronamraju, Jill Maaske, Ricardo Garcia-Sanchez, John P H Wilding. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2020 07; 22(7):1094-1101. doi:
10.1111/dom.14004. [PMID: 32072735] - Hui Fang, Fengmei Xu, Jin Du, Li Liang, Wei Li, Liya Shen, Xueying Wang, Chun Xu, Fang Bian, Yiming Mu. Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.
Journal of diabetes investigation.
2020 Jul; 11(4):896-905. doi:
10.1111/jdi.13224. [PMID: 32020731] - Ziwei Zhang, Xiang Yan, Chao Wu, Xieyi Pei, Xia Li, Xiangbing Wang, Xiaohong Niu, Hongwei Jiang, Xiaomin Zeng, Zhiguang Zhou. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.
Diabetes/metabolism research and reviews.
2020 07; 36(5):e3298. doi:
10.1002/dmrr.3298. [PMID: 32043288] - Zhihui Chen, Jing Yu, Menglu Fu, Ruolan Dong, Yan Yang, Jinlan Luo, Shuiqing Hu, Wenhua Li, Xizhen Xu, Ling Tu. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
Biochemical pharmacology.
2020 07; 177(?):113951. doi:
10.1016/j.bcp.2020.113951. [PMID: 32251672] - Vala Hamidi, Kayla Riggs, Liang Zhu, Karla Bermudez Saint Andre, Christian Westby, Sara Coverdale, Amy Dursteler, Hongyu Wang, Charles Miller Iii, Heinrich Taegtmeyer, Absalon D Gutierrez. Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
Metabolic syndrome and related disorders.
2020 06; 18(5):225-233. doi:
10.1089/met.2019.0102. [PMID: 32228379] - Yuanyuan Hu, Shandong Ye, Yan Xing, Lijuan Lv, Wen Hu, Wan Zhou. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats.
Acta diabetologica.
2020 Mar; 57(3):279-286. doi:
10.1007/s00592-019-01421-7. [PMID: 31535208] - Wen Li, Ruixin Liu, Xuelin Li, Bei Tao, Nan Zhai, Xiaolin Wang, Qi Li, Yifei Zhang, Weiqiong Gu, Weiqing Wang, Guang Ning. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.
Journal of diabetes.
2019 Dec; 11(12):982-992. doi:
10.1111/1753-0407.12956. [PMID: 31141297] - Mai M Helmy, Samar M Mouneir. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Pharmacological reports : PR.
2019 Dec; 71(6):1133-1139. doi:
10.1016/j.pharep.2019.06.017. [PMID: 31675669] - David D Berg, Stephen D Wiviott, Benjamin M Scirica, Yared Gurmu, Ofri Mosenzon, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Per Johanson, Peter A Johansson, Anna Maria Langkilde, Itamar Raz, Eugene Braunwald, Marc S Sabatine. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Circulation.
2019 11; 140(19):1569-1577. doi:
10.1161/circulationaha.119.042685. [PMID: 31474116] - J Koska, T Osredkar, K D'Souza, M Sands, S Sinha, W Zhang, C Meyer, P D Reaven. Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study.
Diabetic medicine : a journal of the British Diabetic Association.
2019 11; 36(11):1399-1407. doi:
10.1111/dme.13889. [PMID: 30580454] - Nada M Kamel, Mai A Abd El Fattah, Hanan S El-Abhar, Dalaal M Abdallah. Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways.
European journal of pharmacology.
2019 Oct; 861(?):172620. doi:
10.1016/j.ejphar.2019.172620. [PMID: 31437429] - Julio Rosenstock, Shira Perl, Eva Johnsson, Ricardo García-Sánchez, Stephan Jacob. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Diabetes, obesity & metabolism.
2019 09; 21(9):2152-2162. doi:
10.1111/dom.13795. [PMID: 31144431] - Masato Kajikawa, Tatsuya Maruhashi, Takayuki Hidaka, Shogo Matsui, Haruki Hashimoto, Yuji Takaeko, Yukiko Nakano, Satoshi Kurisu, Yasuki Kihara, Farina Mohamad Yusoff, Shinji Kishimoto, Kazuaki Chayama, Chikara Goto, Kensuke Noma, Ayumu Nakashima, Takafumi Hiro, Atsushi Hirayama, Kazuki Shiina, Hirofumi Tomiyama, Shusuke Yagi, Rie Amano, Hirotsugu Yamada, Masataka Sata, Yukihito Higashi. Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study.
Scientific reports.
2019 07; 9(1):10206. doi:
10.1038/s41598-019-46726-3. [PMID: 31308448] - Carol Pollock, Bergur Stefánsson, Daniel Reyner, Peter Rossing, C David Sjöström, David C Wheeler, Anna Maria Langkilde, Hiddo J L Heerspink. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
The lancet. Diabetes & endocrinology.
2019 06; 7(6):429-441. doi:
10.1016/s2213-8587(19)30086-5. [PMID: 30992195] - Katherine R Tuttle. SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.
The lancet. Diabetes & endocrinology.
2019 06; 7(6):414-415. doi:
10.1016/s2213-8587(19)30116-0. [PMID: 30992196] - Juan-Juan Li, Ping Zhang, Bing Fan, Xiu-Li Guo, Zhe-Shu Zheng. The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Revista da Associacao Medica Brasileira (1992).
2019 Jan; 65(1):33-37. doi:
10.1590/1806-9282.65.1.33. [PMID: 30758417] - Per Lundkvist, Maria J Pereira, Prasad G Kamble, Petros Katsogiannos, Anna Maria Langkilde, Russell Esterline, Eva Johnsson, Jan W Eriksson. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism.
2019 01; 104(1):193-201. doi:
10.1210/jc.2018-00969. [PMID: 30137410] - Yang Yang, Yunhong Lu, Fei Han, Yunpeng Chang, Xiaoyu Li, Zhe Han, Mei Xue, Ying Cheng, Bei Sun, Liming Chen. Saxagliptin regulates M1/M2 macrophage polarization via CaMKKβ/AMPK pathway to attenuate NAFLD.
Biochemical and biophysical research communications.
2018 09; 503(3):1618-1624. doi:
10.1016/j.bbrc.2018.07.090. [PMID: 30060948] - Kuanlin Chen, Tiejun Zhuo, Jian Wang, Qing Mei. Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Metabolic syndrome and related disorders.
2018 09; 16(7):336-341. doi:
10.1089/met.2018.0010. [PMID: 29912623] - Manar Gamal Helal, Marwa Mohamed Abdel Fattah Zaki, Eman Said. Nephroprotective effect of saxagliptin against gentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatory and anti-apoptic effects.
Life sciences.
2018 Sep; 208(?):64-71. doi:
10.1016/j.lfs.2018.07.021. [PMID: 30012474] - Jessica Fernandes, M Vivek Ghate, Sanchari Basu Mallik, Shaila A Lewis. Amino acid conjugated chitosan nanoparticles for the brain targeting of a model dipeptidyl peptidase-4 inhibitor.
International journal of pharmaceutics.
2018 Aug; 547(1-2):563-571. doi:
10.1016/j.ijpharm.2018.06.031. [PMID: 29906562] - Lujin Wu, Ke Wang, Wei Wang, Zheng Wen, Peihua Wang, Lei Liu, Dao Wen Wang. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.
Aging cell.
2018 08; 17(4):e12763. doi:
10.1111/acel.12763. [PMID: 29659121] - Julio Rosenstock, Chantal Mathieu, Hungta Chen, Ricardo Garcia-Sanchez, Gabriela Luporini Saraiva. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Archives of endocrinology and metabolism.
2018 08; 62(4):424-430. doi:
10.20945/2359-3997000000056. [PMID: 30304106] - Huan Huang, Sharash Shetty, Elise Bauer, Kathleen Lang. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Current medical research and opinion.
2018 06; 34(6):1021-1027. doi:
10.1080/03007995.2017.1416346. [PMID: 29231750] - Gulay Nephan, Zeynep Mine Coskun, Sema Bolkent. Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance.
Cell biochemistry and function.
2018 Jun; 36(4):212-220. doi:
10.1002/cbf.3333. [PMID: 29748970] - Thomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, Matthias M Weber, Stephan Voswinkel, Tim Heise, Christoph Kapitza, Leona Plum-Mörschel. Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2018 May; 50(5):403-407. doi:
10.1055/a-0591-9442. [PMID: 29727906] - Ying Peng, Qingqing Chang, Na Yang, Shiyin Gu, Yi Zhou, Lifang Yin, Jiye Aa, Guangji Wang, Jianguo Sun. Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Apr; 1081-1082(?):109-117. doi:
10.1016/j.jchromb.2018.02.007. [PMID: 29518719] - Yingli Chen, Xiaomin Liu, Quanmin Li, Jianhua Ma, Xiaofeng Lv, Lixin Guo, Changjiang Wang, Yongquan Shi, Yanbing Li, Eva Johnsson, Mei Wang, June Zhao, Linong Ji. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
Diabetes, obesity & metabolism.
2018 04; 20(4):1044-1049. doi:
10.1111/dom.13161. [PMID: 29144061] - Yochai Birnbaum, Mandeep Bajaj, Hsiu-Chiung Yang, Yumei Ye. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Cardiovascular drugs and therapy.
2018 04; 32(2):135-145. doi:
10.1007/s10557-018-6778-x. [PMID: 29508169] - Jingtao Dou, Jianhua Ma, Jun Liu, Changjiang Wang, Eva Johnsson, Hui Yao, June Zhao, Changyu Pan. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Diabetes, obesity & metabolism.
2018 03; 20(3):590-598. doi:
10.1111/dom.13117. [PMID: 28926170] - Tao Tao, Peihong Wu, Yuying Wang, Wei Liu. Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
BMC endocrine disorders.
2018 Feb; 18(1):14. doi:
10.1186/s12902-018-0243-5. [PMID: 29482528] - Benjamin M Scirica, Ofri Mosenzon, Deepak L Bhatt, Jacob A Udell, Ph Gabriel Steg, Darren K McGuire, KyungAh Im, Estella Kanevsky, Christina Stahre, Mikaela Sjöstrand, Itamar Raz, Eugene Braunwald. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
JAMA cardiology.
2018 02; 3(2):155-163. doi:
10.1001/jamacardio.2017.4228. [PMID: 29214305] - Peng Men, Xiao-Tong Li, Hui-Lin Tang, Suo-di Zhai. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.
PloS one.
2018; 13(5):e0197321. doi:
10.1371/journal.pone.0197321. [PMID: 29787616] - André J Scheen. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Expert review of clinical pharmacology.
2017 Dec; 10(12):1303-1316. doi:
10.1080/17512433.2017.1389645. [PMID: 28984487] - Masako Uchii, Mariko Sakai, Yuhei Hotta, Satoshi Saeki, Naoya Kimoto, Akinori Hamaguchi, Tetsuya Kitayama, Shunji Kunori. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
Journal of pharmacological sciences.
2017 Nov; 135(3):126-130. doi:
10.1016/j.jphs.2017.10.003. [PMID: 29113790] - Cristina Hernández, Patricia Bogdanov, Cristina Solà-Adell, Joel Sampedro, Marta Valeri, Xavier Genís, Olga Simó-Servat, Marta García-Ramírez, Rafael Simó. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
Diabetologia.
2017 Nov; 60(11):2285-2298. doi:
10.1007/s00125-017-4388-y. [PMID: 28779212] - Scott M Brown, Cassandra E Smith, Alex I Meuth, Maloree Khan, Annayya R Aroor, Hannah M Cleeton, Gerald A Meininger, James R Sowers, Vincent G DeMarco, Bysani Chandrasekar, Ravi Nistala, Shawn B Bender. Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice.
Endocrinology.
2017 10; 158(10):3592-3604. doi:
10.1210/en.2017-00416. [PMID: 28977602] - Pia S Pollack, Kristina D Chadwick, David M Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal, David W Boulton. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Cardiovascular diabetology.
2017 09; 16(1):113. doi:
10.1186/s12933-017-0595-6. [PMID: 28903775] - Zixuan Wang, Dengcheng Xu, Lanhui Huang, Tiantian Zhang, Junqiao Wang, Qing Chen, Lei Kong, Xinli Zhou. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Diabetes research and clinical practice.
2017 Aug; 130(?):77-85. doi:
10.1016/j.diabres.2017.05.012. [PMID: 28575729] - André J Scheen. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Clinical pharmacokinetics.
2017 07; 56(7):703-718. doi:
10.1007/s40262-016-0498-9. [PMID: 28039605] - Fang Li, Jiachao Chen, Fei Leng, Zhiqiang Lu, Yan Ling. Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
2017 Jun; 125(6):400-407. doi:
10.1055/s-0042-124421. [PMID: 28407661] - Yumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, Jose R Perez-Polo, Yochai Birnbaum. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Cardiovascular drugs and therapy.
2017 Apr; 31(2):119-132. doi:
10.1007/s10557-017-6725-2. [PMID: 28447181] - Priyanka A Shah, Jaivik V Shah, Mallika Sanyal, Pranav S Shrivastav. LC-MS/MS analysis of metformin, saxagliptin and 5-hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed-dose formulation in healthy Indian subjects.
Biomedical chromatography : BMC.
2017 Mar; 31(3):. doi:
10.1002/bmc.3809. [PMID: 27508356] - Ella Ekholm, Lars Hansen, Eva Johnsson, Nayyar Iqbal, Björn Carlsson, Hungta Chen, Boaz Hirshberg. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2017 Mar; 23(3):258-265. doi:
10.4158/ep161323.or. [PMID: 27849380] - David W Boulton. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Clinical pharmacokinetics.
2017 01; 56(1):11-24. doi:
10.1007/s40262-016-0421-4. [PMID: 27282159] - Yu-Wei Chen, Jun-Sing Wang, Wayne H-H Sheu, Shih-Yi Lin, I-Te Lee, Yuh-Min Song, Chia-Po Fu, Chia-Lin Lee. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
PloS one.
2017; 12(2):e0171753. doi:
10.1371/journal.pone.0171753. [PMID: 28182722] - Ofri Mosenzon, Gil Leibowitz, Deepak L Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M Scirica, Itamar Raz. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Diabetes care.
2017 Jan; 40(1):69-76. doi:
10.2337/dc16-0621. [PMID: 27797925] - Karen E Elkind-Hirsch, Martha S Paterson, Ericka L Seidemann, Hanh C Gutowski. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
Fertility and sterility.
2017 01; 107(1):253-260.e1. doi:
10.1016/j.fertnstert.2016.09.023. [PMID: 28228317] - Shira Perl, William Cook, Cheryl Wei, Peter Ohman, Boaz Hirshberg. Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Clinical therapeutics.
2016 Dec; 38(12):2578-2588. doi:
10.1016/j.clinthera.2016.10.006. [PMID: 27823868] - Weiqiong Gu, Li Liang, Shengxiang Wang, Yunzhi Wang, Yanxiang Wu, Jian Tian, Gangyi Yang, Chunli Piao, Yuzhong Li, Jianmei Yin, Xiaoping Xin, Xingrong Tan, Guang Ning, Weiqing Wang. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
Journal of diabetes.
2016 Nov; 8(6):809-815. doi:
10.1111/1753-0407.12360. [PMID: 26676908] - C Mathieu, M Herrera Marmolejo, J G González González, L Hansen, H Chen, E Johnsson, R Garcia-Sanchez, N Iqbal. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2016 11; 18(11):1134-1137. doi:
10.1111/dom.12737. [PMID: 27385192] - Feng-Fei Li, Lan-Lan Jiang, Reng-Na Yan, Hong-Hong Zhu, Pei-Hua Zhou, Dan-Feng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
Medicine.
2016 Oct; 95(43):e5229. doi:
10.1097/md.0000000000005229. [PMID: 27787387] - Lin Wang, Peicheng Li, Zhaosheng Tang, Xinfeng Yan, Bo Feng. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.
Scientific reports.
2016 09; 6(?):33251. doi:
10.1038/srep33251. [PMID: 27633081] - Blisse Vakkalagadda, Susan Lubin, Laurie Reynolds, Dan Liang, Alan S Marion, Frank LaCreta, David W Boulton. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.
Clinical therapeutics.
2016 Aug; 38(8):1890-9. doi:
10.1016/j.clinthera.2016.07.005. [PMID: 27491280] - Abigail Tebboth, Sally Lee, Anna Scowcroft, Paula Bingham-Gardiner, Will Spencer, John Bolodeoku, Syed Wasi Hassan. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Clinical therapeutics.
2016 Aug; 38(8):1825-1832.e15. doi:
10.1016/j.clinthera.2016.07.006. [PMID: 27491279] - Masako Uchii, Naoya Kimoto, Mariko Sakai, Tetsuya Kitayama, Shunji Kunori. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
European journal of pharmacology.
2016 Jul; 783(?):56-63. doi:
10.1016/j.ejphar.2016.04.005. [PMID: 27063445] - Masanori Abe, Terumi Higuchi, Masari Moriuchi, Masahiro Okamura, Ritsukou Tei, Chinami Nagura, Hiroyuki Takashima, Fumito Kikuchi, Hyoe Tomita, Kazuyoshi Okada. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Diabetes research and clinical practice.
2016 Jun; 116(?):244-52. doi:
10.1016/j.diabres.2016.04.034. [PMID: 27321342] - E Bonora, B Bryzinski, B Hirshberg, W Cook. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Nutrition, metabolism, and cardiovascular diseases : NMCD.
2016 05; 26(5):374-9. doi:
10.1016/j.numecd.2015.11.004. [PMID: 27033025] - Muralikrishna Gangadharan Komala, Simon Gross, Amgad Zaky, Carol Pollock, Usha Panchapakesan. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Nephrology (Carlton, Vic.).
2016 May; 21(5):423-31. doi:
10.1111/nep.12618. [PMID: 26375854] - Jessica A Hiemstra, Dong I Lee, Khalid Chakir, Manuel Gutiérrez-Aguilar, Kurt D Marshall, Pamela J Zgoda, Noelany Cruz Rivera, Daniel G Dozier, Brian S Ferguson, Denise M Heublein, John C Burnett, Carolin Scherf, Jan R Ivey, Gianmaria Minervini, Kerry S McDonald, Christopher P Baines, Maike Krenz, Timothy L Domeier, Craig A Emter. Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.
Journal of the American Heart Association.
2016 Apr; 5(4):e003277. doi:
10.1161/jaha.116.003277. [PMID: 27098966] - R Buzzetti, P Pozzilli, R Frederich, N Iqbal, B Hirshberg. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
Diabetes/metabolism research and reviews.
2016 Mar; 32(3):289-96. doi:
10.1002/dmrr.2717. [PMID: 26385269] - L A Leiter, H Teoh, O Mosenzon, A Cahn, B Hirshberg, C A M Stahre, J B L Hoekstra, M Alvarsson, K Im, B M Scirica, D L Bhatt, I Raz. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Diabetes, obesity & metabolism.
2016 Feb; 18(2):186-90. doi:
10.1111/dom.12582. [PMID: 26443993] - Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Diabetes care.
2015 Nov; 38(11):2009-17. doi:
10.2337/dc15-0779. [PMID: 26246458] - Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal, Lars Hansen. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
Diabetes care.
2015 Nov; 38(11):2018-24. doi:
10.2337/dc15-0811. [PMID: 26324329] - Nicolangelo Iazzetta, Carlo Garofalo, Manuela Savino, Adelia Sagliocca, Sara Santangelo, Mario Pacilio, Maria Elena Liberti, Andrea Camocardi, Camilla Ambrosca, Roberto Minutolo, Luca De Nicola, Giuseppe Conte. Nephroprotection with saxagliptin.
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2015 Nov; 32(6):. doi:
NULL. [PMID: 26845214] - Mariko Sakai, Masako Uchii, Kensuke Myojo, Tetsuya Kitayama, Shunji Kunori. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
European journal of pharmacology.
2015 Aug; 761(?):109-15. doi:
10.1016/j.ejphar.2015.04.023. [PMID: 25936515] - G Schernthaner, S Durán-Garcia, M Hanefeld, G Langslet, L Niskanen, C J Östgren, E Malvolti, E Hardy. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Diabetes, obesity & metabolism.
2015 Jul; 17(7):630-8. doi:
10.1111/dom.12461. [PMID: 25761977] - N Batta, N R Pilli, V R Derangula, H B Vurimindi, R Damaramadugu, R P Yejella. A rapid and sensitive LC-MS/MS assay for the determination of saxagliptin and its active metabolite 5-hydroxy saxagliptin in human plasma and its application to a pharmacokinetic study.
Drug research.
2015 Mar; 65(3):133-40. doi:
10.1055/s-0034-1374616. [PMID: 24941084] - Noha N Nassar, Muhammad Y Al-Shorbagy, Hany H Arab, Dalaal M Abdallah. Saxagliptin: a novel antiparkinsonian approach.
Neuropharmacology.
2015 Feb; 89(?):308-17. doi:
10.1016/j.neuropharm.2014.10.007. [PMID: 25446674] - Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Journal of medical economics.
2015; 18(10):808-20. doi:
10.3111/13696998.2015.1049542. [PMID: 25950193] - Peter P Toth. Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.
Vascular health and risk management.
2015; 11(?):9-23. doi:
10.2147/vhrm.s75215. [PMID: 25565858] - Anders Gummesson, Haiyan Li, Michael Gillen, John Xu, Mohammad Niazi, Boaz Hirshberg. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects.
Clinical drug investigation.
2014 Nov; 34(11):763-72. doi:
10.1007/s40261-014-0230-1. [PMID: 25269885] - Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini, Pia S Pollack, Boaz Hirshberg, Robert Frederich, Basil S Lewis, Darren K McGuire, Jaime Davidson, Ph Gabriel Steg, Deepak L Bhatt. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Circulation.
2014 Oct; 130(18):1579-88. doi:
10.1161/circulationaha.114.010389. [PMID: 25189213] - William Cook, Gianmaria Minervini, Brian Bryzinski, Boaz Hirshberg. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Postgraduate medicine.
2014 Oct; 126(6):19-32. doi:
10.3810/pgm.2014.10.2818. [PMID: 25414932] - Mikaela Sjöstrand, Nayyar Iqbal, Jane Lu, Boaz Hirshberg. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Diabetes research and clinical practice.
2014 Aug; 105(2):185-91. doi:
10.1016/j.diabres.2014.05.006. [PMID: 24947443] - Yan Liu, Zhen Zhang, Rongping Chen, Jia Sun, Hong Chen. [Therapeutic effect of saxagliptin in rat models of nonalcoholic fatty liver and type 2 diabetes].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2014 Jun; 34(6):862-8. doi:
". [PMID: 24968846] - Christian Ott, Ulrike Raff, Stephanie Schmidt, Iris Kistner, Stefanie Friedrich, Peter Bramlage, Joanna M Harazny, Roland E Schmieder. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.
Cardiovascular diabetology.
2014 Jan; 13(?):19. doi:
10.1186/1475-2840-13-19. [PMID: 24423149] - German Ramirez, Anthony D Morrison, Polly A Bittle. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2013 Nov; 19(6):1025-34. doi:
10.4158/ep12306.ra. [PMID: 23757605] - William Cook, Brian Bryzinski, Jill Slater, Robert Frederich, Elsie Allen. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Postgraduate medicine.
2013 May; 125(3):145-54. doi:
10.3810/pgm.2013.05.2657. [PMID: 23748515]